Watson Announces Filing of New Drug Application (NDA) for Oxybutynin Patch

Apr 27, 2001, 01:00 ET from Watson Pharmaceuticals, Inc.

    CORONA, Calif., April 27 /PRNewswire/ -- Watson Pharmaceuticals, Inc.
 (NYSE:   WPI) today announced that it has filed a New Drug Application (NDA)
 with the Food and Drug Administration (FDA) for its oxybutynin transdermal
 system in the treatment of overactive bladder.  The NDA is based on clinical
 results obtained from a recently completed placebo controlled Phase III trial
 in over 500 patients.
     Overactive bladder, a condition characterized by symptoms of urinary
 frequency, urgency and urge incontinence, may be treated with anti-cholinergic
 drugs, such as oxybutynin, since these agents can stabilize the bladder muscle
 and reduce the urgent sensations to urinate, leading to urinary frequency and
 incontinence.
     Allen Chao, Ph.D., Watson's Chairman and Chief Executive Officer
 commented:  "We believe our product can provide a unique therapeutic option
 for patients suffering from overactive bladder.  If approved, this product
 will be a key component in our commitment to women's health and to urology,
 further expanding our portfolio of products in these important areas."
     Watson Pharmaceuticals, Inc., headquartered in Corona, California, is a
 leading specialty pharmaceutical company that develops, manufactures, markets
 and distributes branded and generic pharmaceutical products.  Watson pursues a
 growth strategy combining internal product development, strategic alliances
 and collaborations and synergistic acquisitions of products and businesses.
 Watson believes this three-pronged growth strategy will allow it to continue
 to expand its branded and generic product offerings with the long-term goal of
 a mix favoring branded products.
     This press release contains certain statements of a forward-looking nature
 relating to future events or future business performance.  Any such statements
 that refer to Watson's estimated or anticipated future results, product
 development efforts or performance, prospects for regulatory approval of its
 products or other non-historical facts are forward-looking and reflect
 Watson's current perspective of existing trends and information.  These
 forward-looking statements involve risks and uncertainties that cannot be
 predicted or quantified and, consequently, actual results may differ
 materially from those expressed or implied by such statements.  These risks
 and uncertainties include, among others, risks related to the success of
 Watson's product development efforts and the difficulty of predicting the
 outcome of such efforts or the timing or outcome of actions of FDA and other
 governmental agencies (including FDA's acceptance of the NDA filing described
 above); and such other risks and uncertainties detailed in Watson's most
 recent filings with the Securities and Exchange Commission, including Watson's
 Form 10-K for the year ended December 31, 2000.
     This and past press releases of Watson Pharmaceuticals, Inc. are available
 at Watson's web site at www.watsonpharm.com.  In addition, press releases are
 available through PR Newswire's Company On-Call fax service at 800-758-5804,
 extension 112856, and at www.prnewswire.com.
 
                      MAKE YOUR OPINION COUNT - Click Here
                http://tbutton.prnewswire.com/prn/11690X21876975
 
 

SOURCE Watson Pharmaceuticals, Inc.
    CORONA, Calif., April 27 /PRNewswire/ -- Watson Pharmaceuticals, Inc.
 (NYSE:   WPI) today announced that it has filed a New Drug Application (NDA)
 with the Food and Drug Administration (FDA) for its oxybutynin transdermal
 system in the treatment of overactive bladder.  The NDA is based on clinical
 results obtained from a recently completed placebo controlled Phase III trial
 in over 500 patients.
     Overactive bladder, a condition characterized by symptoms of urinary
 frequency, urgency and urge incontinence, may be treated with anti-cholinergic
 drugs, such as oxybutynin, since these agents can stabilize the bladder muscle
 and reduce the urgent sensations to urinate, leading to urinary frequency and
 incontinence.
     Allen Chao, Ph.D., Watson's Chairman and Chief Executive Officer
 commented:  "We believe our product can provide a unique therapeutic option
 for patients suffering from overactive bladder.  If approved, this product
 will be a key component in our commitment to women's health and to urology,
 further expanding our portfolio of products in these important areas."
     Watson Pharmaceuticals, Inc., headquartered in Corona, California, is a
 leading specialty pharmaceutical company that develops, manufactures, markets
 and distributes branded and generic pharmaceutical products.  Watson pursues a
 growth strategy combining internal product development, strategic alliances
 and collaborations and synergistic acquisitions of products and businesses.
 Watson believes this three-pronged growth strategy will allow it to continue
 to expand its branded and generic product offerings with the long-term goal of
 a mix favoring branded products.
     This press release contains certain statements of a forward-looking nature
 relating to future events or future business performance.  Any such statements
 that refer to Watson's estimated or anticipated future results, product
 development efforts or performance, prospects for regulatory approval of its
 products or other non-historical facts are forward-looking and reflect
 Watson's current perspective of existing trends and information.  These
 forward-looking statements involve risks and uncertainties that cannot be
 predicted or quantified and, consequently, actual results may differ
 materially from those expressed or implied by such statements.  These risks
 and uncertainties include, among others, risks related to the success of
 Watson's product development efforts and the difficulty of predicting the
 outcome of such efforts or the timing or outcome of actions of FDA and other
 governmental agencies (including FDA's acceptance of the NDA filing described
 above); and such other risks and uncertainties detailed in Watson's most
 recent filings with the Securities and Exchange Commission, including Watson's
 Form 10-K for the year ended December 31, 2000.
     This and past press releases of Watson Pharmaceuticals, Inc. are available
 at Watson's web site at www.watsonpharm.com.  In addition, press releases are
 available through PR Newswire's Company On-Call fax service at 800-758-5804,
 extension 112856, and at www.prnewswire.com.
 
                      MAKE YOUR OPINION COUNT - Click Here
                http://tbutton.prnewswire.com/prn/11690X21876975
 
 SOURCE  Watson Pharmaceuticals, Inc.